Circulating microRNAs and serum proteins in breast cancer patients: Diagnostic relevance and grade-specific expression patterns

Figure 1 Relative expression values for the selected panel of microRNAs (miR-21, miR-221, miR-1246, miR-145, and miR-382) in breast cancer patients (grade II and grade III) and healthy controls. Significance at ^aP < 0.05 compared to healthy control; significance at ^bP < 0.05 between grade II and grade III. MiRNAs: MicroRNAs.

Figure 2 Serum levels of 8-hydroxy-2′-deoxyguanosine (pg/mL) and cancer antigen 15-3 (U/mL). Significance at ^aP < 0.05 compared to healthy control; significance at ^bP < 0.05 between grade II and grade III. CA15-3: Cancer antigen 15-3; 8-OhdG: 8-hydroxy-2′-deoxyguanosine.

Figure 3 Receiver operating characteristic curve analysis demonstrating the diagnostic performance of selected microRNAs and protein tumor biomarkers in differentiating breast cancer patients (grade II) from healthy controls. AUC: Area under the curve; CA15-3: Cancer antigen 15-3; MiRNAs: MicroRNAs; 8-OhdG: 8-hydroxy-2′-deoxyguanosine.

Figure 4 Receiver operating characteristic curve analysis demonstrating the diagnostic performance of selected microRNAs and protein tumor biomarkers in differentiating breast cancer patients (grade III) from healthy controls. AUC: Area under the curve; CA15-3: Cancer antigen 15-3; MiRNAs: MicroRNAs; 8-OhdG: 8-hydroxy-2′-deoxyguanosine.

Figure 5 Receiver operating characteristic curve analysis demonstrating the diagnostic performance of selected microRNAs and protein tumor biomarkers in differentiating breast cancer patients (grade II vs grade III). AUC: Area under the curve; CA15-3: Cancer antigen 15-3; MiRNAs: MicroRNAs; 8-OhdG: 8-hydroxy-2′-deoxyguanosine.